Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics initiated a Phase 2 basket trial to evaluate Ebribafusp, a complement inhibitor acquired from Q32 Bio, for rare complement-mediated kidney diseases including IgAN, lupus nephritis, and C3 glomerulopathy. The open-label study expects to enroll up to 30 patients receiving weekly subcutaneous dosing for 26 weeks, with initial data anticipated in 2027.
Key figures
- Drug Name
- Ebribafusp
- Phase Of Trial
- Phase 2
- Prevalence us
- 200000
- Dosing frequency
- weekly subcutaneous
- Data readout year
- 2027
- Patient enrollment
- 30
- Trial duration weeks
- 26
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.